Sign In
Buy KHTRF
$5.99
+0.0800 (+1.35%)
At Close: Jun 03, 2026
Knight Therapeutics Inc. (KHTRF) Q4 2024 Earnings Call Transcript
02:35pm, Thursday, 20'th Mar 2025
Knight Therapeutics Inc. (OTCPK:KHTRF) Q4 2024 Earnings Conference Call March 20, 2025 8:30 AM ET Company Participants Samira Sakhia - President and Chief Executive Officer Arvind Utchanah - Chief Fin
Knight Therapeutics Reports Fourth Quarter and Year-End 2024 Results
07:30am, Thursday, 20'th Mar 2025
MONTREAL, March 20, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a pan-American (ex-US) specialty pharmaceutical company, today reported financial resu
Notice of Knight Therapeutics' Fourth Quarter and Year End 2024 Results Conference Call
07:30am, Thursday, 13'th Mar 2025
MONTREAL, March 13, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, will release its fourth quarter and year end
MONTREAL and LUGANO, Switzerland, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a pan-American (ex-USA) specialty pharmaceutical company, and Helsinn Healthcare
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Mexico
07:30am, Thursday, 12'th Dec 2024
MONTREAL, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, announced today that its Mexican affiliate, Grupo
Knight Therapeutics Inc. (KHTRF) Q3 2024 Earnings Call Transcript
06:36am, Saturday, 09'th Nov 2024
Knight Therapeutics Inc. (OTCPK:KHTRF) Q3 2024 Earnings Conference Call October 7, 2024 8:30 AM ET Company Participants Samira Sakhia – President and Chief Executive Officer Arvind Utchanah – Chie
Knight Therapeutics Reports Third Quarter 2024
07:30am, Thursday, 07'th Nov 2024
MONTREAL, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financi
Notice of Knight Therapeutics' Third Quarter 2024 Results Conference Call
07:30am, Thursday, 31'st Oct 2024
MONTREAL, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its third quarter 2024 fi
Knight Therapeutics Inc. places No. 397 on The Globe and Mail's sixth annual ranking of Canada's Top Growing Companies
10:22am, Friday, 27'th Sep 2024
MONTREAL, Sept. 27, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) (“Knight” or “the Company”) is pleased to announce it has ranked No. 397 on the 2024 Report on Business magazine
Knight Therapeutics Reports Second Quarter 2024
07:30am, Thursday, 08'th Aug 2024
MONTREAL, Aug. 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan- American (ex-US) specialty pharmaceutical company, today reported financ
Notice of Knight Therapeutics' Second Quarter 2024 Results Conference Call
07:30am, Thursday, 01'st Aug 2024
MONTREAL, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) (“Knight”), a leading pan-American (ex-USA) specialty pharmaceutical company, will release its second quarter 2024 f
Knight Therapeutics, Inc. (KHTRF) Q1 2024 Earnings Call Transcript
03:53am, Saturday, 11'th May 2024
Knight Therapeutics, Inc. (OTCPK:KHTRF) Q1 2024 Earnings Conference Call May 9, 2024 8:30 AM ET Company Participants Samira Sakhia - President & CEO Amal Khouri - CBO Arvind Utchanah - CFO Conference
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusi
Knight Therapeutics Reports First Quarter 2024 Results
07:30am, Thursday, 09'th May 2024
MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight" or “the Company”), a leading pan-American (ex-US) specialty pharmaceutical company, today reported financia
Knight Therapeutics Inc. announces voting results from the Annual General Meeting
06:32pm, Wednesday, 08'th May 2024
MONTREAL, May 08, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX:GUD) ("Knight" or the "Corporation") a leading pan-American (ex-US) specialty pharmaceutical company, announced today the votin
